Just over 10 years ago, the first agent for HIV pre-exposure prophylaxis was approved in the United States. Since then, the landscape of PrEP has shifted, with approval of additional PrEP medications and growth of low-threshold PrEP delivery strategies, such as same-day PrEP. In this interactive webinar, participants will learn about new medications in the pipeline for PrEP and emerging PrEP delivery models.
